Literature DB >> 23061545

Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.

Ruby Yun-Ju Huang1, Vin Yee Chung, Jean Paul Thiery.   

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Discovery of novel therapeutic opportunities for EOC is important for the improvement of clinical outcome of the patients. Emerging evidence is suggesting that epithelial-mesenchymal transition (EMT) plays a crucial role in the aggressiveness in EOC including increasing migration and invasion ability, contributing to chemoresistance and cancer stem cell populations. Targeting EMT in EOC thus offers an attractive therapeutic option.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23061545     DOI： 10.2174/138945012803530044

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN： 1389-4501            Impact factor:   3.465


  37 in total

1.  Osthole inhibited TGF β-induced epithelial-mesenchymal transition (EMT) by suppressing NF-κB mediated Snail activation in lung cancer A549 cells.

Authors:  Haitao Feng; Jin-Jian Lu; Yitao Wang; Lixia Pei; Xiuping Chen
Journal:  Cell Adh Migr       Date:  2017-02-02       Impact factor: 3.405

2.  An essential role for heat shock transcription factor binding protein 1 (HSBP1) during early embryonic development.

Authors:  Binnur Eroglu; Jin-Na Min; Yan Zhang; Edyta Szurek; Demetrius Moskophidis; Ali Eroglu; Nahid F Mivechi
Journal:  Dev Biol       Date:  2013-12-28       Impact factor: 3.582

3.  Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.

Authors:  Sophia Sn Lam; Abby Sc Mak; Judy Wp Yam; Annie Ny Cheung; Hextan Ys Ngan; Alice St Wong
Journal:  Mol Ther       Date:  2014-01-14       Impact factor: 11.454

4.  Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

Authors:  Y He; A C Wu; B S Harrington; C M Davies; S J Wallace; M N Adams; J S Palmer; D K Roche; B G Hollier; T F Westbrook; H Hamidi; G E Konecny; B Winterhoff; N P Chetty; A J Crandon; N B Oliveira; C M Shannon; A V Tinker; C B Gilks; J I Coward; J W Lumley; L C Perrin; J E Armes; J D Hooper
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

5.  Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior.

Authors:  Yanxin Wang; Yi-Shiou Chiou; Qing-Yun Chong; Mengyi Zhang; Kanchuragoppal S Rangappa; Lan Ma; Tao Zhu; Alan Prem Kumar; Ruby Yun-Ju Huang; Vijay Pandey; Peter E Lobie
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-09

6.  MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.

Authors:  Xiaolin Liu; Ruifen Dong; Zhijun Jiang; Yuyan Wei; Yingwei Li; Linxuan Wei; Hengzi Sun; Yinuo Li; Ning Yang; Qifeng Yang; Zhaojian Liu; Beihua Kong
Journal:  Tumour Biol       Date:  2015-01-16

7.  Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells.

Authors:  Kamola Saydaminova; Robert Strauss; Min Xie; Jiri Bartek; Maximilian Richter; Ruan van Rensburg; Charles Drescher; Anja Ehrhardt; Sheng Ding; André Lieber
Journal:  Cancer Biol Ther       Date:  2016-08-30       Impact factor: 4.742

8.  Advantages of the avian model for human ovarian cancer.

Authors:  Ana DE Melo Bernardo; Sólveig Thorsteinsdóttir; Christine L Mummery
Journal:  Mol Clin Oncol       Date:  2015-08-11

9.  SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.

Authors:  Haitao Tang; Jiaxin Zhao; Liangyu Zhang; Jiang Zhao; Yongzhi Zhuang; Peng Liang
Journal:  Cell Mol Neurobiol       Date:  2015-12-07       Impact factor: 5.046

10.  The essential roles of CCR7 in epithelial-to-mesenchymal transition induced by hypoxia in epithelial ovarian carcinomas.

Authors:  Shaomei Cheng; Lin Han; Jingyan Guo; Qing Yang; Jianfang Zhou; Xiangshan Yang
Journal:  Tumour Biol       Date:  2014-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.